Supplementary Information




Figure S1. Development of LFRET signals in follow-up samples. a) Days post onset of COVID-19 symptoms (x-axis) vs anti-N LFRET signal (y-axis) (N=38 samples from 16 individuals). b) Days post positive SARS-CoV-2 PCR (x-axis) vs anti-N LFRET signal (y-axis) (N=53 samples from 22 individuals). c) Days post onset of COVID-19 symptoms (x-axis) vs anti-S LFRET signal (y-axis) (N=38 samples from 16 individuals). d) Days post positive SARS-CoV-2 PCR (x-axis) vs anti-S LFRET signal (y-axis) (N=53 samples from 22 individuals). Horizontal line is the LFRET cutoff. S = spike glycoprotein. N = nucleocapsid protein. LFRET = protein L-based time-resolved Förster resonance energy transfer immunoassay.




Figure S2. SARS-CoV-2 spike glycoprotein (S) versus nucleocapsid protein (N) ELISA. a) anti-S vs. anti-N IgA ELISA results (N=81, R=0.31) b) anti-S vs. anti-N IgG ELISA results (N=129, R=0.90). c) anti-S vs. anti-N IgM ELISA results (N=81, R=0.79). On the x-axis, anti-S ELISA absorbance, on the y-axis anti-N ELISA absorbance. Colour of the dot indicates SARS-CoV-2 PCR result and disease severity: cyan = PCR negative; yellow = non-hospitalized, PCR-positive; red = non-ICU hospitalized, PCR positive; black = hospitalized in ICU, PCR positive. Horizontal and vertical lines indicate ELISA cutoffs. R = Pearson's correlation coefficient.




Figure S3. LFRET vs. severity of disease in samples taken after two weeks from onset of disease. a) Severity of disease (x-axis) vs. anti-S LFRET (y-axis) b) Severity of disease (x-axis) vs. anti-N LFRET (y-axis). Negative = samples from comprehensively SARS-CoV-2 seronegative individuals (N=52). Non-hospitalized = samples from non-hospitalized COVID-19 patients (N=27). Samples from hospitalized individuals with COVID-19 (N=12) are grouped together to include samples from individuals treated outside of ICU (N=3) and in ICU (N=9). Horizontal lines indicate LFRET cutoffs (thin grey lines) and mean LFRET signal (thick black lines). Logarithmic scale is used on the y-axis. Differences between groups are statistically significant, as indicated by the p values within the figure. S = spike glycoprotein. N = nucleocapsid protein. LFRET = protein L-based time-resolved Förster resonance energy transfer immunoassay.




Figure S4. Receiver operating character (ROC) curves for LFRET. a) anti-N LFRET. AUC = 0.94. b) anti-S LFRET. AUC = 0.97. False positive rate on the x-axis, true positive rate on the y-axis. Enzyme immunoassay (IgA, IgG and IgM results combined) is used as the reference. N = nucleocapsid protein. S = spike glycoprotein. LFRET = protein L—based time-resolved Förster resonance energy transfer immunoassay.

Table S1. Agreement between ELISA and LFRET. Ig ELISA = IgA, IgG and IgM results combined: if any of these are positive, total Ig is considered positive. N/S ELISA/LFRET: if either N or S ELISA/LFRET is positive, the N/S result is considered positive. Number of samples in brackets. S = spike glycoprotein. N = nucleocapsid protein. LFRET = protein L-based time-resolved Förster resonance energy transfer immunoassay. ELISA = enzyme immunoassay. MNT = microneutralization titer.

	anti-N Ig	anti-N IgG	anti-S Ig	anti-S IgG	anti N/S Ig	anti N/S
	ELISA	ELISA	ELISA	ELISA	ELISA	IgG ELISA
N LFRET	88% (113/129)	89% (115/129)	91% (117/129)	90% (116/129)	87% (112/129)	89% (115/129)
S	93% (120/129)	95%	96%	98%	92%	95%
LFRET		(122/129)	(124/129)	(127/129)	(119/129)	(122/129)
N/S	95%	96%	98%	97%	94%	96%
LFRET	(122/129)	(124/129)	(126/129)	(125/129)	(121/129)	(124/129)

Table S2. Detailed information on samples with discordance between PCR, LFRET and ELISA results. Sample = sample id. NAT = nucleic acid testing result for SARS-CoV-2. S = spike glycoprotein. N = nucleocapsid protein. LFRET = protein L-based time-resolved Förster resonance energy transfer immunoassay. ELISA = enzyme immunoassay. MNT = microneutralization titer. + = result above cutoff. - = result below cutoff. Hosp. = Hospitalized, non-ICU. ICU = Hospitalized in ICU. Home = non-hospitalized. Neg. = no disease. NA = not available.

Sa	NA	Sever	Days	Days	anti-S	anti-N	anti-	anti-	anti-	anti-	anti-	anti-	MNT
mpl	Т	ity of	from	from	LFRE	LFRE	S	S	S	N	N	N	
e		disea	onset	NAT	T	Т	ELIS	ELIS	ELIS	ELIS	ELIS	ELIS	
		se	of				A	A	A	A	A	A	
			symp				IgA	IgG	IgM	IgA	IgG	IgM	
			toms										
71	+	Hosp	8	2	-	-	-	-	-	+	-	-	<20
65	+	ICU	8	1	-	-	-	-	-	-	-	-	<20
72	+	ICU	8	2	-	-	-	-	-	-	-	-	<20
70	+	ICU	13	4	-	-	-	-	-	+	-	-	20
7	+	Hom	30	24	-	-	+	+	_	+	+	-	<20
		e											
24	+	Hom	66	60	-	-	-	+	-	+	+	-	<20
		e											
86	+	Hosp	NA	2	-	-	-	-	-	-	-	-	<20
82	-	Neg.	27	25	-	-	-	-	-	-	+	-	NA
92	-	Neg.	134	NA	-	-	-	-	-	-	+	-	<20
103	NA	Neg.	NA	NA	-	-	-	-	NA	NA	+	NA	<20
121	NA	Neg.	NA	NA	-	-	+	-	NA	NA	-	NA	<20

Table S3. Sensitivity and specificity of LFRET/ELISA in detecting microneutralization positive (titer ≥ 20) samples. S = spike glycoprotein. N = nucleocapsid protein. LFRET = protein L-based time-resolved Förster resonance energy transfer immunoassay. ELISA = enzyme immunoassay. Only 4 negative samples were tested in anti-N IgA and IgM as well as anti-S IgM ELISA, and thus specificity of these assays needs to be assessed with caution.

	anti-S	anti-N	anti-S	anti-S	anti-S	anti-N	anti-N	anti-N
	LFRET	LFRET	IgA	IgG	IgM	IgA	IgG	IgM
			ELISA	ELISA	ELISA	ELISA	ELISA	ELISA
Sensitivity	98%	92%	98%	98%	79%	88%	98%	20%
Specificity	91%	96%	85%	87%	93%	64%	82%	100%